Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranexa MERLIN Trial Could Support First-Line Angina, Acute Coronary Syndrome Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

CV Therapeutics says 5,500-patient Ranexa outcomes trial in ACS patients expected to begin in fourth quarter under a special protocol assessment with FDA. An absence of a trend towards death or arrhythmia would be sufficient for first-line chronic angina claim, firm says.

You may also be interested in...



CVT To Co-Promote Solvay's Aceon In Preparation For Ranexa Launch

CVT's 150-rep sales force will be used to promote the ACE inhibitor Aceon as well as the angina therapy Ranexa, which could launch in 2006. Aceon sales growth is tied to outcomes data expected to be added to labeling in 2005, CVT says.

CVT To Co-Promote Solvay's Aceon In Preparation For Ranexa Launch

CVT's 150-rep sales force will be used to promote the ACE inhibitor Aceon as well as the angina therapy Ranexa, which could launch in 2006. Aceon sales growth is tied to outcomes data expected to be added to labeling in 2005, CVT says.

CV Therapeutics Ranexa Benefit Over Norvasc Will Be Focus Of Additional Phase III Trial

Refractory angina trial designed under a special protocol assessment with FDA will begin in the third quarter. The company predicts a "broad restricted label" based on the study, which follows recommendations made by FDA's Cardio-Renal Drugs Advisory Committee.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel